A Canadian startup refuels to take on a rare cardiac condition that many patients don't realize they have
A year and a half ago, a small biotech launched out of Laval, Quebec to one-up beta blockers for the treatment of a rare heart condition that often goes undiagnosed. Now, a slate of investors is reaching deeper into the pockets to drive the company’s push toward the clinic.
LQT Therapeutics unveiled a $19 million Series A round on Tuesday to bring its lead compound for Long QT syndrome (LQTS) through Phase I. LQTS is a genetic disorder that causes an elongation between the Q and T waves during a heartbeat, which can lead to rapid, chaotic heartbeats or arrhythmias. Patients with the condition suffer fainting spells, seizures, cardiac arrest or sudden death.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.